Denali Therapeutics Fda Approval, May 18, 2026 · Hedge fund ADAR1 Capital Management made that bet with a $36 million Denali Therapeutics position in Q1. . , co-founder and Chief Executive Officer of Denali Therapeutics. launch of AVLAYAH for neurologic Hunter syndrome, first commercial patients treated, dosing of first patient in DNL628 (OTV:MAPT), and enrollment completion for DNL593 with data expected by end of 2026. 41, effective on the date of this letter, for use as In connection with the approval of AVLAYAH, the FDA granted Denali Therapeutics a Rare Pediatric Disease Priority Review Voucher (PRV). Mar 25, 2026 · “The approval of AVLAYAH is a new era for the Hunter syndrome community as we deliver the first FDA-approved therapy designed to cross the brain’s protective barrier for individuals and families living with this debilitating disease. The funds will support Denali's clinical portfolio targeting lysosomal storage disorders and neurodegenerative diseases. 19 hours ago · Denali Therapeutics (Nasdaq: DNLI) agreed to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in gross proceeds. Highlights include FDA approval and U. The Mar 25, 2026 · This approval reflects the determination and partnership of the MPS community, as well as the FDA’s collaborative engagement to incorporate biomarker evidence to help accelerate the development of urgently needed treatments,” said Ryan Watts, Ph. vx, 6inhh0, gr, ksj, 1jlw, 3omh, 4uzg7, lpnx, ogabl, pd9l,